HomeMost PopularInvestingThe Meteoric Rise of Arcturus: Unleashing Growth Amid Turbulent Times

The Meteoric Rise of Arcturus: Unleashing Growth Amid Turbulent Times

Actionable Trade Ideas

always free

Arcturus Therapeutics Holdings Inc. has seen an exceptional surge of 73% in its stock value over the past three months, dwarfing the industryโ€™s modest growth of 10.5%.

In a groundbreaking move, the European Commission recently accorded orphan medicinal product status to ARCT-032, Arcturusโ€™ potential treatment for cystic fibrosis (CF). This designation not only bolsters ARCT-032โ€™s development but also offers various advantages to Arcturus, including protocol assistance and market exclusivity for a decade upon regulatory approval.

Only a month earlier, the FDA granted Orphan Drug designation to ARCT-032, further solidifying its standing in the CF treatment landscape. The positive momentum could be traced back to these significant milestones achieved by Arcturus.

Arcturus recently announced the successful completion of two administrations of ARCT-032 to the first CF patient in its early-stage study, marking a crucial step forward. The company is well poised to unveil interim data from the phase Ib study in the first half of 2024.

Harnessing its Lunar lipid-mediated aerosolized platform, ARCT-032 represents a revolutionary mechanism for delivering cystic fibrosis transmembrane conductance regulator (CFTR) messenger RNA to the lungs, showcasing Arcturusโ€™ innovative approach and commitment to addressing critical health challenges.

Cystic fibrosis, a devastating genetic disorder, disrupts the bodyโ€™s mucus-producing cells due to faulty CFTR gene mutations, leading to severe damages in vital organs like the lungs and digestive system. Arcturusโ€™ strides in CF treatment underscore the companyโ€™s dedication to combating life-threatening conditions.

Beyond its CF endeavors, Arcturus has ventured into groundbreaking territory with the development of the worldโ€™s first self-amplifying messenger RNA (sa-mRNA) COVID vaccine. Japan granted approval to ARCT-154, the sa-mRNA COVID-19 vaccine, for initial vaccination and booster doses for adults aged 18 and above, reflecting Arcturusโ€™ global impact.

The approval of ARCT-154 and the ongoing advancement of ARCT-032 signal a promising trajectory for Arcturus in the forthcoming year.

Arcturus Therapeutics Holdings Inc. Elevates on the Chart

Arcturus Therapeutics Holdings Inc. Price

Behold the Arcturus Therapeutics Holdings Inc. Pricing Dynamics | Arcturus Therapeutics Holdings Inc. Quote

Zacks Rank & Gems to Consider

Arcturus currently holds a Zacks Rank of #3 (Hold).

In the healthcare realm, there are superior stock options like Indivior PLC INDV, Vanda Pharmaceuticals Inc. VNDA, and Kiniksa Pharmaceuticals, Ltd. KNSA, each adorned with a Zacks Rank of #1 (Strong Buy) presently. A peek intoย Zacks #1 Rank picks for today reveals insightful choices for investors.

Over the past 60 days, the anticipated 2024 earnings per share for Indivior surged from $1.83 to $1.95, reflecting an optimistic outlook. INDV showcased a 13.2% rise in its share value over the last year.

Noteworthy is Indiviorโ€™s consistent earnings beat over the preceding three quarters, yielding a remarkable average earnings surprise of 48.06%.

Within the same timeframe, the Zacks Consensus Estimate for Vanda Pharmaceuticals in 2024 witnessed a transformation from a loss of 46 cents per share to earnings of 1 cent, exuding improved financial health. Despite a 27.2% dip in its share value over the past year, VNDA has unveiled exceptional earnings surprises across the last three quarters, averaging at an impressive 92.88%.

Meanwhile, estimates for Kiniksa Pharmaceuticalsโ€™ 2024 loss per share underwent a significant reduction, shrinking from 53 cents to 7 cents within the preceding 60 days. Riding a impressive 74.2% rise in its share value over the past year, KNSA demonstrated strong earnings performance, surpassing estimates in two of the last four quarters and yielding a four-quarter average earnings surprise of 53.19%.

Unlock the Potent Pick for Doubling Returns

Delve into the top choices identified by 5 Zacks experts to skyrocket +100% or more in the ensuing months. Among these selections, Director of Research Sheraz Mian hand-picks a hidden gem poised for explosive growth.

Spotlighting a lesser-known chemical company, soaring with a remarkable 65% surge over the past year yet with a budget-friendly valuation. Fueled by relentless demand, burgeoning 2022 earnings projections, and a whopping $1.5 billion allocated for share buybacks, this investment beckons retail investors seeking an opportune entry point.

Could this contender outmatch or even outpace renowned Zacksโ€™ Stocks Set to Double like Boston Beer Company, witnessing a staggering surge of +143.0% in just over nine months, or NVIDIA, soaring by an impressive +175.9% over a year?

Donโ€™t Miss Out: Unveil Our Top Stock and 4 Runners Up >>

Searching for the Latest Recommendations from Zacks Investment Research? Gain instant access to 7 Best Stocks for the Upcoming 30 Days. Click to download the report for free

Zacks Investment Research

Itโ€™s crucial to discern that the expressed viewpoints and perspectives in this article solely represent the authorโ€™s stance and may not align with those of Nasdaq, Inc.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.